Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Long-Term Debt Issuances: 2014-2023

  • Viridian Therapeutics, Inc.\DE's Long-Term Debt Issuances was N/A to $15.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $16.2 million, marking a year-over-year change of. This contributed to the annual value of $15.0 million for FY2023, which is 200.00% up from last year.
  • As of Q3 2023, Viridian Therapeutics, Inc.\DE's Long-Term Debt Issuances stood at $15.0 million, which was up 3,263.23% from $446,000 recorded in Q4 2022.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Long-Term Debt Issuances ranged from a high of $15.0 million in Q3 2023 and a low of $446,000 during Q4 2022.
  • For the 2-year period, Viridian Therapeutics, Inc.\DE's Long-Term Debt Issuances averaged around $7.7 million, with its median value being $7.7 million (2022).